Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Byetta exenatide: Phase III data

In a double-blind, international Phase III trial in 232 treatment-naïve patients, 5 and 10 µg

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE